Neuralink’s secondary market pricing currently implies valuations between roughly $15 billion and $53 billion as of early October 2026, well above the June 2025 Series E post-money of approximately $9.7 billion, with share quotes near $150. Recent clinical updates—including reduced daily calibration times for implant users and new BCI performance records above 11 bits per second—alongside expanded preclinical work such as the first feline implant, have sustained investor interest in the brain-computer interface sector. With the October 31 resolution date approaching, trader sentiment hinges on any near-term secondary transactions or fresh funding marks that could confirm or revise these levels before month-end, amid rising competition from peers like Precision Neuroscience.